Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | SPR | P35270 | 6/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106553 | 0.90 | HSD11B1 (0.54) | HSD11B1KDM4DPDE10AUSP30SPR | |
| SCHEMBL12021484 | 0.90 | HSD11B1 (0.54) | HSD11B1KDM4DPDE10AUSP30SPR | |
| SCHEMBL10106549 | 0.90 | HSD11B1 (0.54) | HSD11B1KDM4DPDE10AUSP30SPR | |
| SCHEMBL10196708 | 0.87 | HSD11B1 (0.49) | HSD11B1KDM4DPDE10AUSP30SPR | |
| SCHEMBL10196718 | 0.87 | HSD11B1 (0.49) | HSD11B1KDM4DPDE10AUSP30SPR | |
| SCHEMBL13561970 | 0.87 | HSD11B1 (0.49) | HSD11B1KDM4DPDE10AUSP30SPR | |
| SCHEMBL16530071 | 0.85 | HSD11B1 (0.50) | HSD11B1KDM4DPDE10AUSP30SPR | |
| SCHEMBL14805846 | 0.84 | HSD11B1 (0.45) | HSD11B1KDM4DASGR1PDE10AUSP30 | |
| SCHEMBL23795137 | 0.82 | HSD11B1 (0.50) | HSD11B1KDM4DASGR1PDE10AUSP30 | |
| SCHEMBL18711272 | 0.82 | HSD11B1 (0.50) | HSD11B1KDM4DASGR1USP30SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2021214469-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
| EP-3616753-A1 | COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | HSD11B1 2807/4885KDM4D 4234/4885ASGR1 219/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | HSD11B1 191/4885KDM4D 2041/4885ASGR1 3528/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | HSD11B1 191/4885KDM4D 2041/4885ASGR1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.